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Introduction
• The pathophysiological concept 
selected for analysis is malignant 
hyperthermia (MH).  
• Relevant in both the intensive 
care unit and the operating room 
while intubating patients or 
inducing anesthesia.  
• Anesthetic inhalation agents like 
halothane and the neuromuscular 
blocking agent succinylcholine can 
trigger a pathological response 
involving intracellular calcium 
resulting in hyper-metabolism 
(Schneiderbanger, Johannsen, 
Roewer & Schuster, 2014, p. 356-
357).  
• It is vital for anesthesia 
professionals and critical care 
nurses to recognize MH and act 
quickly to limit rapid shifts of 
electrolytes (Donnelly, 1994, p. 
395). 
Underlying Pathophysiology References (cont.)
• Malignant hyperthermia is an autosomal dominant trait with a 
mutation of the ryanodine receptor (RYR1) (Hirshey Dirksen, et al., 
2011, p. 1108).  
• When exposed to an environmental (heat stroke) or pharmacological 
trigger, the mutation on RYR1 causes an uncontrolled release of 
calcium from the sarcoplasmic reticulum in skeletal muscles 
(Rosenberg, Pollock, Schiemann, Bulger & Stowell, 2015, p. 4).  
• The only other gene showing potential MH-causing mutation is 
CACNA1S (Rosengerg, et al., 2015, p. 4).  
• The depolarizing muscle relaxant succinylcholine and volatile 
anesthetics including halothane, isoflurane, enflurane, sevoflurane, 
methoxyflurane, and desflurane can all trigger MH (Schneiderbanger, 
et al., 2014, p. 356-357).
• The uncontrolled release of calcium in the muscle leads to sustained 
contraction causing a rise in exhaled carbon dioxide, the observable 
muscle rigidity, and generates heat which leads to a dramatic rise in 
body temperature (Seifert, Wahr, Pace, Cochrane & Bagnola, 2014, p. 
189).  
• When muscles become rigid they can no longer produce adenosine 
triphosphate (ATP) which leads to cellular damage and leakage of 
potassium, creatine kinase, and myoglobin from the muscle cells 
(Brandom & Callahan, 2015, p. 115).  
• This leakage results in metabolic acidosis, cardiac arrhythmias, and 
myoglobinuria (Brandom & Callahan, 2015, p. 115).  
• To compensate for the increased body temperature, 
hyperventilation, vasodilation, and catecholamine release all occur 
which lead to increased end-tidal carbon dioxide levels, flushing, and 
tachycardia followed by cyanosis of the periphery (Brandom & 
Callahan, 2015, p. 115).  
• If not halted this hypermetabolic state can lead to cardiac arrest, 
hemorrhaging, and brain damage (Ali, Taguchi & Rosenberg, 2003).  
• Malignant hyperthermia is a rare 
and life-threatening condition which 
is elicited by anesthetic agents used 
during intubation and general 
anesthesia (Cain, Riess, Gettrust & 
Novalija, 2014, p. 301).  
• It is vital that nurses and anesthesia 
providers know what to monitor and 
what actions to take if a patient 
develops MH.  
• Simulations can assist in preparing 
personnel for a potential MH crisis 
in a safe environment, and this 
practice has been used regularly by 
anesthesia professionals since 1994 
(Cain et al., 2014, p. 302).  
• MHAUS has organized mock drills 
with the funding help of professional 
anesthesia associations and is a 
valuable data bank for families and 
anesthesia providers on malignant 
hyperthermia (Brandom & Callahan, 
2015, p. 124).  
• Future research on MH will likely 
focus on genetics and the 
phenotypic variability of RYR1-
related conditions (Hirshey Dirksen, 
2011, p. 1110).  
• Accurately predicting which patients 
are susceptible to MH will allow 
providers to avoid possible 
triggering agents while still 
providing excellent anesthetic care 
to those patients. 
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• Dantrolene blocks the release of calcium 
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• Beta blockers and oxygen are also needed to 
treat the tachycardia and hypoxia associated 
with MH (Lilley et al., 2007, p. 171).  
• Cooling the patient and correcting 
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• Supportive care and dantrolene 
administration will continue from the 
operating room (OR) to the intensive care 
unit (ICU) for at least forty-eight hours of 
monitoring and continued care (Ali, et al., 
2003, p. 526). 
• Screening patients preoperatively can 
prevent MH episodes before they happen.  
• A thorough individual (including muscular 
pathologies) and family health history can 
identify patients at risk for MH, since it can 
be an inherited condition (Schneiderbanger, 
et al., 2014, p. 360).  
• Muscular disorders including Central Core 
Disease, Myotonic Muscular Dystrophy, and 
King-Denborough syndrome are all conditions 
predisposed to developing MH (Rosenberg, 
et al., 2015, p. 3-4).  
• Testing can be performed to determine 
susceptibility of MH in at-risk individuals with 
the caffeine halothane contracture test 
(CHCT) (Hirshey Dirksen, et al., 2011, p. 
1112).  During the test caffeine and 
halothane are applied directly to muscle 
bundles and will cause contracture at lower 
concentrations in MH susceptible patients 
(Hopkins, 2017, p. 323).  
• Families with the RYR1 mutation are referred 
to the Malignant Hyperthermia Registry also 
known as MHAUS for entry into the national 
database (Myers, 2009, p. 1136).  
Implications
• Hallmark and earliest sign of malignant 
hyperthermia is hypercapnia which can 
be detected as an increase in end-tidal 
carbon dioxide or EtCO2 (Lin et al., 
2014, p. 209).  
• Other major signs of MH include 
muscle rigidity, tachycardia, tachypnea, 
pyrexia, flushing followed by 
peripheral mottling, cardiac 
arrhythmias, hypotension, 
rhabdomyolysis, and even 
disseminated intravascular coagulation 
(Brandom & Callahan, 2015, p.119).  
Signs and Symptoms of MH
• Both metabolic and respiratory acidosis can 
develop simultaneously resulting in a 
profound acidotic state (Redmond, 2001, p. 
261).  
• Symptoms can result in what appears to be 
a comatose-state for the patient with 
absent reflexes, fixed pupils, apnea, and 
unconsciousness (Huether, McCance, 
Brashers & Rote, 2008, p. 314).
• Malignant hyperthermia is life-threatening and is associated with administration of 
anesthetic agents and neuromuscular blocking agents.  
• It can occur rapidly, or slightly delayed, in any facility that administers the potential 
triggering agents.  This means that reactions can occur in the operating room (OR), 
post anesthesia care unit (PACU), or the intensive care unit (ICU) (Seifert, et al., 
2014, p. 190).    
• Without proper recognition, the affected patient can suffer dire consequences.  
Cardiac arrest, disseminated intravascular coagulation, kidney failure, liver failure, 
brain damage, and even death are potential outcomes if treatment is not initiated 
and supportive care provided (Seifert, et al.,2014, p. 189).  
• This makes the pathophysiology of MH extremely significant and it is vital that the 
anesthesia provider, PACU nurse or ICU nurse recognize the condition so it can be 
treated. 
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